Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2017 Nov 7.
Published in final edited form as: Bioorg Med Chem Lett. 1996 Sep 17;6(18):2151–2156. doi: 10.1016/0960-894X(96)00366-6

α-VINYLLYSINE AND α-VINYLARGININE ARE TIME-DEPENDENT INHIBITORS OF THEIR COGNATE DECARBOXYLASES

David B Berkowitz 1,*, Wan-Jin Jahng 1, Michelle L Pedersen 1
PMCID: PMC5675568  NIHMSID: NIHMS892502  PMID: 29123334

Abstract

(±)-α-Vinyllysine and (±)-α-vinylarginine display time-dependent inhibition of L-lysine decarboxylase from B. cadaveris, and L-arginine decarboxylase from E. coli, respectively. A complete Kitz-Wilson analysis has been performed using a modification of the Palcic continuous UV assay for decarboxylase activity.


As part of a program directed at the synthesis of new, α-branched amino acids, we have previously described a convenient method for the synthesis of α-vinyl amino acids,1a,b and for their enzymatic resolution.1c We have also established that α-vinyl amino acids are useful precursors to the corresponding α-chlorovinyl,1d α-bromovinyl1d and α-oxiranyl amino acids.1e Herein, we provide a detailed kinetic characterization of two new time-dependent inhibitors of the α-vinyl amino acid class.

Several α-vinyl amino acids are known to act as mechanism-based inhibitors for pyridoxal phosphate dependent enzymes. The simplest α-vinyl amino acid, α-vinylglycine, is a natural product2 and inactivates transaminases for L-aspartate, L-alanine, L-serine and D-alanine.3a–e One decarboxylase, L-cysteine sulfinate decarboxylase, is also irreversibly inactivated by α-vinylglycine.3f Peptidylglycine α-hydroxylating monooxygenase (PHM) is irreversibly inhibited by a D-α-vinylglycine-containing tripeptide.4

The higher vinyl amino acids (with R groups,, more complex than hydrogen) are not known natural products, though a considerable number have been synthesized.1a,5 Previous work has shown that DOPA decarboxylase,6 ornithine decarboxylase7 and glutamate decarboxylase,8 all important medicinal targets, are irreversibly inhibited by the corresponding (±)-α-vinyl amino acids. In the cases of α-vinylhistidine6a and α-vinylserine9 (reversible) competitive inhibition is observed with the PLP-dependent histidine decarboxylase and with serine hydroxymethyltransferase, respectively. A related vinyl amino acid, γ-vinyl-GABA (Vigabatrin) is a time-dependent inhibitor of GAB A transaminase and an anti-epileptic drug.10 Elegant studies by Silverman and coworkers have provided useful insights into the mechanism of action of this γ-vinyl-γ-amino acid.11

graphic file with name nihms892502u1.jpg

Using our formal vinylation procedure,1a we synthesized (±)-α-vinylarginine (1) and (±)-α-vinyllysine (2) as potential mechanism-based inhibitors of L-arginine decarboxylase (ADC) and L-lysine decarboxylase (LDC), respectively. Indeed, several other a-branched (primarily α-halogenomethyl) amines and amino acids have been developed by others as mechanism-based inhibitors of ADC12 and LDC.13 These two amino acid decarboxylases are important targets for the development of antiproliferative agents as their reaction products feed into the polyamine pathway. The ADC reaction product, agmatine, is converted to putrescine via agmatine amidinohydrolase (agmatinase; EC 1.5.3.11). The LDC reaction product, cadaverine, is used as a putrescine-surrogate in a modified polyamine pathway found in tumor cells that have been exposed to ornithine DC inhibitors.14 ADC inhibitors are also potential antibiotics as this enzyme is found in bacterial and plants, but not in mammalian systems.12

Time-Dependent Inhibition Kinetics

We wished to use a continuous UV assay to evaluate (±)-α-vinylarginine and (±)-α-vinyllysine for time-dependent inhibition of their cognate decarboxylases in contrast to the radioactive, time-point assay that has been traditionally used.68 We chose to develop a modified version of the assay described by Palcic and coworkers.15 In this assay, the CO2 formed upon decarboxylation is trapped by phosphoenolpyruvate carboxylase (PEPC)-mediated condensation with PEP to produce oxaloacetate. Subsequent in situ reduction of the oxaloacetate to L-malate with malate dehydrogenase results in a decrease in O.D.340 due to the oxidation of NADH to NAD+. Whereas Palcic used a CO2 kit for this assay, we chose to assemble each of the individual components, and in so doing, to optimize the assay in terms of pH and source and amount of each enzyme, in particular. Our optimal conditions are presented below. These assay conditions were first tested for each enzyme by carrying out a standard Lineweaver-Burk steady state kinetic analysis with the natural substrate. In this way, we obtained Km = 180 μM for L-arginine with arginine decarboxylase (Figure 1) and Km = 640 μM for L-lysine with lysine decarboxylase (Figure 2).

Figure 1.

Figure 1

Figure 2.

Figure 2

Optimized Continuous UV Assay for Decarboxylase Activity

General

The assay cuvet (total volume 1 mL) contained 80 mM potassium phosphate buffer (pH 6.8), 2 mM L-lysine, 0.4 mM PLP, 0.01 U lysine DC (Bacterium cadaveris, 55 U/mg protein, single band on SDS-PAGE), 2 mM PEP, 10 mM MgCl2, 0.9 U PEPC (Zea mays), 0.04 U carbonic anhydrase, 1.5 U malate dehydrogenase, 0.21 mM NADH.

Time-dependent inhibition assays

Et cuvet: the enzyme was incubated with (±)-α-vinyllysine and all other components with the exception of lysine. Eo cuvet: A control cuvet identical to the Et cuvet, but lacking inhibitor, was incubated under the same conditions. After incubation of both cuvets at 25° C for a time t, background rates for each cuvet were measured by monitoring ΔO.D.340 vs. time.* L-lysine (2 mM) was then added to each cuvet and initial rates were measured as before. For primary plots, Et/Eo was calculated as follows: Et = vo[(LDC + I) + L-lys]t − vo(LDC + I)t and Eo = vo(LDC + L-lys)t−vo(LDC)t.

For arginine DC (E. Coli., 215 U/mg protein, single band on SDS-PAGE), the same procedure was followed except that all incubations and assays were run at pH 6.5.

Then, for each inhibitor and each enzyme, a complete Kitz-Wilson analysis16 was performed. This involves pre-incubating a given decarboxylase with a fixed concentration of its cognate α-vinyl amino acid inhibitor candidate (vide supra). The slope of the primary plot (ln(E/Eo) vs. time of incubation) corresponds to an apparent inactivation constant for that inhibitor concentration. After repeating the experiment at several inhibitor concentrations, a secondary plot {reciprocal kinact(apparent) versus 1/[} is constructed, the intercept and slope of which provide kinact and KI, respectively:

Primary Plot: ln(E/E0) = −[kinact/(1 + KI/[I])]t
Secondary Plot: −1/primary slope = 1/kinact(apparent) = (KI/kinact)(I/[I]) + 1/kinact

As can be seen from Figures 36 both (±)-α-vinylarginine and (±)-α-vinyllysine exhibit well-behaved time-dependent inhibition of their cognate DC’s. We obtain, KI = 1.8 mM and kinact = 3.6 × 10−2 min−1 for (±)-α-vinylarginine with L-arginine DC. These data indicate a relatively weak affinity of this enzyme for this α-branched alternative substrate, though the rate of inactivation is quite respectable. On the other hand, (±)-α-vinyllysine displays KI = 0.5 mM and kinact = 2 × 102 min−1 with L-lysine DC. While the observed first order inactivation rate constant here is marginally smaller than that observed for (±)-α-vinylarginine with arginine DC, the KI is respectable. If one considers that the enzyme probably turns over only one enantiomer (subject to future verification) of this apparent Trojan horse inhibitor, the KI is actually about 250 μM, which is nearly a factor of three smaller than Km. This indicates that an α-vinyl substituent is particularly well-tolerated by LDC. Furthermore, dialysis of inhibited LDC against several changes of buffer (conditions under which LDC activity does not decrease) fails to restore any LDC activity, indicating that the observed inhibition is irreversible.

Figure 3.

Figure 3

Figure 6.

Figure 6

Summary

Using our procedure for the formal α-vinylation of α-amino acids, (±)-α-vinylarginine and (±)-α-vinyllysine were synthesized. A modification of the continuous UV assay for decarboxylases reported by Palcic was used to conveniently perform a Kitz-Wilson kinetic analysis for time-dependent inhibition with these α-branched amino acids. Indeed, both compounds display pseudo-first order time-dependent inhibition of their respective amino acid decarboxylases, with (±)-α-vinyllysine displaying a KI that compares favorably with Km.

Figure 4.

Figure 4

Figure 5.

Figure 5

Acknowledgments

Financial support from the National Institutes of Health (CA 62034) is gratefully acknowledged. This research was facilitated by grants for shared instrumentation (NMR and GC/MS) from the NIH (SIG 1-S10-RR06301) and the NSF (CHE-93000831), respectively.

References

  • 1.(a) Pedersen ML, Berkowitz DB. J Org Chem. 1993;58:6966–6975. [Google Scholar]; (b) Berkowitz DB, Smith MK. Synthesis. 1996:39–41. doi: 10.1055/s-1996-4177. [DOI] [PMC free article] [PubMed] [Google Scholar]; (c) Berkowitz DB, Pumphrey JA, Shen Q. Tetrahedron Lett. 1994;35:8743–8746. [Google Scholar]; (d) Berkowitz DB, Pedersen ML, Jahng WJ. Tetrahedron Lett. 1996;37:4309–4312. doi: 10.1016/0040-4039(96)00832-5. [DOI] [PMC free article] [PubMed] [Google Scholar]; (e) Berkowitz DB, Pedersen ML. J Org Chem. 1995;60:5368–5369. doi: 10.1021/jo00122a002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Dardenne G, Casimir J, Marlier M, Larsen PO. Phytochemistry. 1974;13:1897–1900. [Google Scholar]
  • 3.(a) Rando RR, Relyea N, Cheng L. J Biol Chem. 1976;251:3306–3312. [PubMed] [Google Scholar]; (b) Rando RR. Biochemistry. 1974;13:3859–3863. doi: 10.1021/bi00716a006. [DOI] [PubMed] [Google Scholar]; (c) Soper TS, Manning JM, Marcotte PA, Walsh CT. J Biol Chem. 1977;252:1571–1575. [PubMed] [Google Scholar]; (d) Cornell NW, Zuurendonk PF, Kerich MJ, Straight CB. Biochem J. 1984;220:707–716. doi: 10.1042/bj2200707. [DOI] [PMC free article] [PubMed] [Google Scholar]; (e) Cho C, Ishii R, Hyeon S, Suzuki A. Agric Biol Chem. 1987;51:2597–2598. [Google Scholar]; (f) Griffith OW. J Biol Chem. 1983;258:1591–1598. [PubMed] [Google Scholar]
  • 4.Zabriskie TM, Cheng H, Vederas JC. J Am Chem Soc. 1992;114:2270–2272. [Google Scholar]
  • 5.(a) Colson P-J, Hegedus LS. J Org Chem. 1993;58:5918–5924. [Google Scholar]; (b) Seebach D, Burger HM, Schickli CP. Liebigs Ann Chim. 1991:669–684. [Google Scholar]; (c) Castelhano AL, Home S, Taylor GJ, Billedeau R, Krantz A. Tetrahedron. 1988;44:5451–5466. [Google Scholar]; (d) Munster P, Steglich W. Synthesis. 1987:223–225. [Google Scholar]; (e) Weber T, Aeschimann R, Maetzke T, Seebach D. Helv Chim Acta. 1986;69:1365–1377. [Google Scholar]; (c) Castelhano AL, Horne S, Billedeau R, Krantz A. Tetrahedron Lett. 1986;27:2435–2438. [Google Scholar]; (d) Steglich W, Wegmann H. Synthesis. 1980:481–483. [Google Scholar]; (e) Metcalf BW, Bonilavri E. J Chem Soc Chem Commun. 1978:914–915. [Google Scholar]; (f) Greenlee WJ, Taub D, Patchett AA. Tetrahedron Lett. 1978:3999–4002. [Google Scholar]; (g) Metcalf, B. W.; Jund, K. Ibid. 1977, 3689–3692;; (h) Taub, D.; Patchett, A. A. Ibid. 1977, 2745–2748;
  • 6.(a) Maycock AL, Aster SD, Patchett AA. Developments in Biochemistry. 1979;6:115–129. [Google Scholar]; (b) Ribereau-Gayon G, Danzin C, Palfreyman MG, Aubry M, Wagner J, Metcalf BW, Jung M. J Biochem Pharm. 1979;28:1331–1335. doi: 10.1016/0006-2952(79)90434-9. [DOI] [PubMed] [Google Scholar]; (c) Maycock AL, Aster SD, Patchett AA. In: Enzyme-Activated Irreversible Inhibitors. Seiler N, Jung MJ, Koch-Weser J, editors. Elsevier; North Holland: 1978. pp. 211–220. [Google Scholar]
  • 7.Danzin C, Casara P, Claverie N, Metcalf BW. J Med Chem. 1981;24:16–20. doi: 10.1021/jm00133a005. [DOI] [PubMed] [Google Scholar]
  • 8.Metcalf B, Jung M. 4,147,873. US Patent. 1979 Apr 3;
  • 9.Tendler SJB, Threadgill MD, Tisdale MJ. J C S Perkin Trans I. 1987:2617–2623. [Google Scholar]
  • 10.Jung MJ, Palfreyman MG. In: Vigabatrin Mechanisms of Action in Antiepileptic Drugs. 4th. Levy RH, Mattson RH, Meldrum BS, editors. Raven, New York: 1995. pp. 903–913. [Google Scholar]
  • 11.Nanavati S, Silverman RB. J Am Chem Soc. 1991;113:9341–9349. [Google Scholar]
  • 12.(a) Christ M, Felix H, Harr JZ. Naturforsch. 1989;44c:49–54. [Google Scholar]; (b) Felix H., Harr, J. Ibid, 1989, 44c, 55–58;; (c) Bitonti AJ, Casara PJ, McCann PP, Bey P. Biochem J. 1987;242:69–74. doi: 10.1042/bj2420069. [DOI] [PMC free article] [PubMed] [Google Scholar]; (d) Kallio A, McCann PP, Bey P. Biochem. 1981;20:3163–3166. doi: 10.1021/bi00514a027. [DOI] [PubMed] [Google Scholar]
  • 13.(a) Yamamoto S, Imamura T, Kusaba K, Shinoda S. Chem Pharm Bull. 1991;39:3067–3070. doi: 10.1248/cpb.39.3067. [DOI] [PubMed] [Google Scholar]; (b) Poso H, McCann PP, Tanskanen R, Bey P, Sjoerdsma A. Biochem Biophys Res Commun. 1984;125:205–210. doi: 10.1016/s0006-291x(84)80355-1. [DOI] [PubMed] [Google Scholar]
  • 14.Alhonen-Hongisto L, Seppanen P, Holtta E, Janne J. Biochem Biophys Res Commun. 1982;106:291–297. doi: 10.1016/0006-291x(82)91108-1. [DOI] [PubMed] [Google Scholar]
  • 15.Scriven F, Wlasichuk KB, Palcic MM. Anal Biochem. 1988;170:367–371. doi: 10.1016/0003-2697(88)90644-6. [DOI] [PubMed] [Google Scholar]
  • 16.Kitz R, Wilson IB. J Biol Chem. 1962;237:3245–3249. [PubMed] [Google Scholar]

RESOURCES